A detailed history of Engineers Gate Manager LP transactions in Fibrogen Inc stock. As of the latest transaction made, Engineers Gate Manager LP holds 85,159 shares of FGEN stock, worth $61,314. This represents 0.01% of its overall portfolio holdings.

Number of Shares
85,159
Previous 85,005 0.18%
Holding current value
$61,314
Previous $75,000 166.67%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.73 - $2.73 $112 - $420
154 Added 0.18%
85,159 $200,000
Q4 2023

Feb 14, 2024

SELL
$0.38 - $0.91 $940 - $2,251
-2,474 Reduced 2.83%
85,005 $75,000
Q3 2023

Nov 14, 2023

SELL
$0.79 - $2.83 $19,599 - $70,212
-24,810 Reduced 22.09%
87,479 $75,000
Q2 2023

Aug 14, 2023

BUY
$2.49 - $20.59 $235,837 - $1.95 Million
94,714 Added 538.91%
112,289 $303,000
Q1 2023

May 15, 2023

BUY
$15.95 - $25.18 $280,321 - $442,538
17,575 New
17,575 $327,000
Q1 2022

May 16, 2022

SELL
$12.02 - $16.79 $208,619 - $291,407
-17,356 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$9.93 - $15.39 $771,908 - $1.2 Million
-77,735 Reduced 81.75%
17,356 $245,000
Q3 2021

Nov 15, 2021

BUY
$10.18 - $26.64 $968,026 - $2.53 Million
95,091 New
95,091 $972,000
Q1 2021

May 17, 2021

SELL
$31.0 - $55.72 $535,773 - $963,008
-17,283 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$37.09 - $48.97 $641,026 - $846,348
17,283 New
17,283 $641,000
Q3 2020

Nov 16, 2020

SELL
$40.47 - $45.5 $251,399 - $282,646
-6,212 Closed
0 $0
Q2 2020

Aug 17, 2020

SELL
$32.57 - $42.83 $16,089 - $21,158
-494 Reduced 7.37%
6,212 $252,000
Q1 2020

May 15, 2020

BUY
$23.3 - $45.96 $156,249 - $308,207
6,706 New
6,706 $233,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $67.5M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.